|
|
 |
 |
 |
Chapter 3: General Principles: Pharmacodynamics
|
|
|
|
|
|
|
With chronic, sustained agonist exposure, the balance of receptor trafficking shifts decisively toward lysosomal degradation.
Receptor protein levels fall due to downregulation and the signaling capacity of the cell is diminished.5,6
This consequence is the cellular correlate of pharmacodynamic tolerance at its most sustained and even if the desensitized, internalized receptors were to be fully re-sensitized, there are simply fewer of them to activate.
Long-term tolerance involves additional, post-receptor adaptations beyond downregulation as described below.
Compensatory upregulation of downstream signaling components
Cells chronically exposed to opioids, which signal via Gαi to suppress cAMP production, upregulate adenylyl cyclase activity and cAMP-responsive signalling machinery.
This homeostatic compensation means that when the opioid is removed, unoppressed adenylyl cyclase generates a surge of cAMP, producing the cellular correlate of opioid withdrawal such as restlessness, autonomic hyperactivity, dysphoria.5
Changes in receptor expression at the transcriptional level
Chronic agonist exposure can suppress receptor gene transcription, reducing the rate of new receptor synthesis and compounding the reduction in receptor number from degradation.
Conversely, chronic antagonist exposure can upregulate receptor gene transcription.
Synaptic and neural circuit adaptations
In the CNS, chronic opioid exposure produces changes in neural circuit connectivity, dendritic morphology, and synaptic strength that extend well beyond individual receptor regulation.
These
between-system adaptations, involving glutamatergic,
noradrenergic, and dopaminergic systems, represent the
neurobiological bases of addiction and the most persistent
component of opioid-related neuroplasticity.1,2
Upregulation and Withdrawal Syndromes
The reciprocal phenomenon, receptor up-regulation in response to chronic receptor blockade, is equally important clinically and equally well characterized mechanistically.
When a receptor is chronically blocked by an antagonist, it is chronically denied its endogenous ligand input.
The cell interprets this as insufficient receptor-mediated signaling and responds with compensatory homeostatic changes:
Increased rate of receptor gene transcription and receptor protein synthesis
Reduced rate of receptor internalization and degradation
Net increase in receptor number and membrane density
Increased receptor sensitivity (often manifest as increased agonist potency and efficacy at the now-upregulated receptor population)8,9,10
When the antagonist is abruptly withdrawn, the now-supranormal receptor population is exposed to physiological concentrations of endogenous agonist.
The response is exaggerated with the rebound exceeding the pre-treatment baseline since there are more and more sensitive receptors than before treatment.
Beta-blocker withdrawal: a clinical example.
Chronic β-adrenoceptor blockade, particularly with non-selective blockers like propranolol, upregulates both β1 and β2 adrenoceptor density in cardiac and other tissues.8.9
The mechanism involves removal of the normal agonist-driven receptor downregulation, resulting in progressive accumulation of receptor protein at the cell surface.
When propranolol is abruptly discontinued,
circulating catecholamines act on this
enlarged receptor population, producing:
Rebound tachycardia and hypertension
Increased myocardial oxygen demand
In patients with coronary artery disease: precipitation of unstable angina or myocardial infarction
Arrhythmias
This is a receptor-mediated, pharmacodynamic not pharmacokinetic withdrawal syndrome
This withdrawal can occur even as plasma propranolol concentrations fall to zero.
Management is gradual tapering over 1–2 weeks, allowing receptor density to normalise before full drug removal.8.9
Additional clinical withdrawal syndromes driven by upregulation
Clonidine acts as an α2-adrenoceptor agonist in the brainstem, reducing central sympathetic outflow and blood pressure.
Chronic clonidine suppresses noradrenaline release, representing negative feedback via presynaptic α2 receptors.
Abrupt withdrawal causes a rebound hypertensive crisis driven by the loss of central sympatholytic effect onto an upregulated sympathetic system. Under these circumstances, blood pressure can rise to dangerously high levels within hours.1,2
Glucocorticoid withdrawal and adrenal insufficiency
Chronic exogenous glucocorticoid administration suppresses the HPA axis via glucocorticoid receptor-mediated negative feedback on hypothalamic CRH and pituitary ACTH secretion.
With prolonged suppression, the adrenal cortex atrophies from lack of ACTH stimulation.
Abrupt withdrawal removes the exogenous glucocorticoid without allowing time for HPA axis recovery.
As a consequence, patients cannot mount a cortisol stress response, resulting in adrenal crisis characterized by potentially fatal hypotension, hypoglycemia, and hyponatremia.
Tapering over weeks to months allows progressive HPA recovery.1,2
Tachyphylaxis is a specific form of rapidly developing tolerance associated with a marked reduction in drug effect that occurs after just one or a few doses, without the weeks of chronic exposure required for true downregulation.
Tachyphylaxis is mechanistically distinct from long-term tolerance and involves different receptor regulatory processes.1,2
The most prominent clinical examples involve mechanisms of rapid depletion or saturation rather than classic GRK/β-arrestin desensitization.
Indirect sympathomimetics (ephedrine, amphetamine) act by triggering presynaptic release of norepinephrine from vesicular stores.
Repeated doses deplete the releasable norepinephrine pool faster than it can be resynthesized.
Subsequent doses have progressively smaller effects (tachyphylaxis) because less norepinephrine is available for release.
Decreasing levels of norepinephrine available for release account for why repeated doses of ephedrine used to treat intraoperative hypotension become progressively less effective and why anesthetists switch to direct adrenoceptor agonists such as phenylephrine or metaraminol if tachyphylaxis develops.
Nitroglycerin tolerance develops within 24 hours of continuous transdermal or intravenous administration as a result of:
(1) Depletion of mitochondrial aldehyde dehydrogenase which is the enzyme responsible for biotransforming nitroglycerin to its active nitric oxide-generating species
(2) Through free radical generation that impairs NO signaling.
A nitrate-free interval of 8–12 hours each day (typically overnight) prevents or reverses this tolerance.
Desensitization-driven tachyphylaxis can occur with any rapidly desensitizing G-protein-coupled receptor (GPCR) system.
Repeated subcutaneous triptan doses such as serotonin 5-HT1B/1D agonists for migraine show diminishing efficacy with each redose within the same migraine attack.
This effect is due to rapid receptor desensitization at the target.
|
|
|
|
|
|
|
|